FOMX Overview
Upcoming Projects (FOMX)
-
Don’t see a project related to the company you care about? Create your own!
Upcoming & Overdue Catalysts (FOMX)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (FOMX)
-
Phase 3 program for FMX103 expected to commence in 2017
Ticker: FOMX
Occurred on: Jun 12, 2017 -
Phase 3 trial of FMX101 top-line results expected in the first half of 2017
Ticker: FOMX
Occurred on: Mar 27, 2017 -
Foamix Announces Completion of Patient Enrollment in Phase 3 Acne Trials for Minocycline Foam FMX101
Ticker: FOMX
Occurred on: Nov 28, 2016 -
Significant Efficacy Achieved in a Phase II Clinical Trial of FMX101
Ticker: FOMX
Occurred on: Sep 12, 2016 -
Topline Results from Phase 2 Trial Evaluating FMX-103 Topical Minocycline Foam for Moderate-to-Severe Papulopustular Rosacea
Ticker: FOMX
Occurred on: Sep 12, 2016 -
Topline Results in Phase 2 Clinical Trial of FMX-103 Minocycline Topical Foam for Moderate-to-Severe Papulopustular Rosacea
Ticker: FOMX
Occurred on: Sep 12, 2016 -
Publication of Abstract on FDX-104 in the Treatment of EGFRI Induced Rash at the 2016 ASCO Meeting
Ticker: FOMX
Occurred on: Jun 06, 2016 -
Dosing of First Patient in Phase 3 Acne Studies for Minocycline Foam FMX101
Ticker: FOMX
Occurred on: May 09, 2016
Strategic Initiatives (FOMX)
-
Foamix Pharmaceuticals (FOMX) becomes a wholly owned subsidiary of Menlo Therapeutics (MNLO)
Tickers: MNLO, FOMX
Announcement Date: Mar 09, 2020
